Alkermes Reports Positive Phase 1b ADHD Data for ALKS 7290
DUBLIN — September 21, 2026 Alkermes announced positive topline results from a Phase 1b proof-of-concept study of ALKS 7290,...
Phase 1b
Advertisement
Corbus Advances CRB-913 Toward Phase 2 in Obesity
NORWOOD, Mass. — September 14, 2026 Corbus Pharmaceuticals Holdings, Inc. announced positive topline results from its CANYON-1 Phase 1b...
Persica Pharmaceuticals Strengthens PP353 Rationale in Lumbar Back Pain
LONDON, UK — September 11, 2026 Persica Pharmaceuticals Limited published a new methodological analysis examining the sensitivity of microbiology...
Cocrystal Pharma Advances CDI-988 in Norovirus Challenge Study
MIAMI, Fla. and BOTHELL, Wash. — September 9, 2026 Cocrystal Pharma, Inc. announced that the last subject has been...
Faeth Therapeutics Highlights PIKTOR Strategy Ahead of Phase 2 Data
AUSTIN, Texas — September 8, 2026 Faeth Therapeutics announced plans to host a virtual key opinion leader (KOL) event...
Advertisements
Persica Strengthens PP353 Case in Vertebrogenic Back Pain
London, UK — September 4, 2026 Persica Pharmaceuticals Limited announced the publication of new antibiotic exposure-response analyses supporting the...
CRISPR Therapeutics Reports Durable CTX310 Lipid Lowering
Zug, Switzerland & Boston, Mass. – August 28, 2026 CRISPR Therapeutics presented new Phase 1a durability data for CTX310,...
Agenus Reports Durable BOT+BAL Activity in MSS Colorectal Cancer
Lexington, Mass. – August 28, 2026 Agenus Inc. announced the publication of mature Phase 1b results evaluating botensilimab (BOT)...
Propanc Advances PRP After Strong Preclinical Pancreatic Cancer Results
Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...
argenx Completes Forte Biosciences Acquisition for FB102
Amsterdam, the Netherlands – August 27, 2026 argenx announced the successful completion of its acquisition of Forte Biosciences, Inc.,...
Advertisement
